Tag: Inogen
Inogen rides B2B tailwind, as POC adoption reshapes channel mix
May 8, 2026Liz Beaulieu, Editor
BEVERLY, Mass. – Inogen’s business-to-business channel is benefiting from the accelerating adoption of portable oxygen concentrators (POCs), a shift that is weighing on its direct-to-consumer and rental channels but creating opportunities to drive additional sales of complementary respiratory products.
“The shift that we see within the U.S. from oxygen tanks to POCs has an impact on both direct-to-consumer, as well as rental patients, which is also creating that tailwind...
Inogen credits ‘power of our strategy’
May 7, 2026HME News Staff
BEVERLY, Mass. - Inogen reported total revenue of $85.1 million for the first quarter of 2026, a 3.4% increase compared to the prior-year period, ahead of the company’s expectations.
Other financial results
Total gross margin was 44.5% in the first quarter of 2026 compared to 44.2% in the prior-year period. Adjusted gross margin improved by 30 basis points to 44.7% compared to 44.4% in the prior-year period due to cost improvements in the total cost of revenue.
GAAP net loss for...
Inogen adds med tech vet to board
April 7, 2026HME News Staff
BEVERLY, Mass. – Inogen has announced that Vafa Jamali will join the company’s board of directors as an independent director effective June 15. As CEO of ZimVie, Jamali led the company’s Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support a turnaround to higher growth and profitability. Prior to ZimVie, he spent nearly 12 years at Covidien and Medtronic, where...
In brief: Inogen’s activist investor, industry’s fraud recs, Apnimed’s financing
April 3, 2026HME News Staff
BEVERLY, Mass. – Inogen has named Vafa Jamali to its board as an independent director and, in connection with that appointment, has entered into a cooperation agreement with Kent Lake Partners.
As CEO of ZimVie, Jamali led the company’s Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support a turnaround to higher growth and profitability. Prior to ZimVie, he spent nearly...
Inogen makes three appointments to exec team
March 31, 2026HME News Staff
BEVERLY, Mass. – Inogen has made three appointments to its executive team in a move the company says will accelerate its next phase of growth. The company has named:
Jason Richardson as CFO, succeeding Michael Bourque, effective April 6;
Dominic Hulton as chief marketing officer, effective April 1; and
Corey Moritz as vice president, U.S. business-to-business sales, who joined on March 9.
Jason Richardson
Richardson joins Inogen from Baxter International Inc., where he most...
Medtrade exhibitors to attendees: We’re all ears
February 27, 2026Tracy Orzel
PHOENIX – With the return of Medicare’s competitive bidding program (CBP) looming large, Medtrade exhibitors are showing up not just to sell, but to listen.
“We understand the uncertainty, risk and operational disruption providers face,” said Kyle Neese, vice president of sales at ACU-Serve. “Providers are looking for real answers, not buzzwords.”
Veterans return with a fresh purpose
That same spirit of dialogue drew Cheryl Henninger, senior consultant...
Inogen hits profitability milestone, grows TAM sixfold with new respiratory products
February 27, 2026Liz Beaulieu, Editor
BEVERLY, Mass. – President and CEO Kevin Smith says 2025 marked a critical turning point for Inogen, with the company delivering adjusted EBITDA profitability for the first time since 2021. Underscoring that progress, Inogen has authorized a $30 million share repurchase program spanning 2026–27.
For the full year, Inogen reported positive adjusted EBITDA of $2.7 million, signaling stabilization after several years of restructuring and portfolio expansion.
“The share repurchase...
Inogen credits discipline in year-over-year improvements
February 25, 2026HME News Staff
BEVERLY, Mass. – Inogen reported total revenue of $81.7 million for the fourth quarter of 2025, a 2% increase compared to the same period last year, primarily driven by higher growth in international portable oxygen concentrator (POC) sales (14.8%), partially offset by lower U.S. sales and U.S. rentals.
Other Q4 financial results:
Total gross margin was 43.1% in the fourth quarter of 2025, a decrease from 45.3% in the prior-year period, primarily...
Mobility is the default setting in home oxygen
February 17, 2026Tracy Orzel
Home respiratory is a cornerstone of the HME industry, but manufacturers and providers are redefining what success in the market looks like: Oxygen therapy that keeps pace with patients, durable equipment for everyday demands, and service models that protect margins.
“Since COVID, we have seen rapid adoption of portable oxygen concentrators (POC) as patients, clinicians and providers increasingly choose POCs over legacy modalities like tanks...
Inogen expects single digit growth for Q4, full year 2025
January 12, 2026HME News Staff
GOLETA, Calif. - Inogen estimates preliminary, unaudited total revenue of about $82 million for the fourth quarter of 2025, representing year-over-year growth of about 2%. Full-year 2025 revenue is expected to be about $349 million, about 4% year-over-year growth, with positive adjusted EBITDA. “While fourth quarter results continued to reflect strong performance in our business-to-business channels, we experienced a shift in the timing of a few large...